

## **Remarks**


Claims 1-9 are pending in the instant application. Applicants have amended claims 1-9 to more fully conform with U.S. practice.

The enclosed substitute specification in compliance with 37 CFR 1.121(b)(3) and 1.125 is for publication purposes and does not contain any markings. It includes a new first paragraph cross referencing the related priority applications.

Applicants also provide herewith a Form PTO-1449 and copies of the non-United States citations. A copy of the published international application, international search report, Written Opinion, and international preliminary examination report from the parent application as well as a copy of the search report from Great Britain which issued on the priority application is also enclosed.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry. Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-9.

Respectfully submitted,



Royal N. Ronning, Jr.  
Registration No.: 32,529  
Attorney for Applicants

**Customer No.: 22840**

Amersham Biosciences Corp  
Patent Department  
800 Centennial Avenue  
Piscataway, New Jersey 08855-1327

Tel: (732) 457-8423  
Fax: (732) 457-8463